Đánh giá hợp chất Technetium-99m gắn với thụ thể Neurokinin-1 nhằm chẩn đoán ung thư thần kinh nội tiết

Lee LS (2010) Diagnosis of pancreatic neuroendocrine tumors and the role of endoscopic ultrasound. Gastroenterol Hepatol 6:520–522 Reznek RH (2006) CT/MRI of neuroendocrine tumours. Cancer Imaging 6:S163–S177 Tamm EP, Bhosale P, Lee JH, Rohren E (2016) State-of-the-art imaging of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am 25:375–400 Maxwell JE, Howe JR (2015) Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol 2:159–168 Tan EH, Tan CH (2011) Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol 2:28–43 Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, Bartenstein P, Pöpperl G (2009) Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765–770 Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM (2015) The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology 101:1–17 Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E (2011) Performance of 18fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥ 10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 96:665–671 van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ (2014) Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol 10:102–114 Krenning EP, Bakker WH, Kooij PPM, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ (1992) Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 33:652–658 Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC (2016) Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med 57:708–714 Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ (2009) Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 50:1214–1221 Munoz M, Covenas R (2010) Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med 10:305–313 Muñoz M, Coveñas R (2013) Involvement of substance P and the NK-1 receptor in cancer progression. Peptides 48:1–9 Muñoz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Investig New Drugs 28:187–193 Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Büchler MW (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Investig 83:731–742 Mantyh PW (2002) Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry 63:6–10 Mozaffari S, Erfani M, Beiki D, Johari Daha F, Kobarfard F, Balalaie S, Fallahi B (2015) Synthesis and preliminary evaluation of a new 99mTc labeled substance P analogue as a potential tumor imaging agent. Iran J Pharm Res 14:97–110 de Araújo EB, Pujatti PB, Barrio O, Caldeira JS, Suzuki MF, Mengatti J (2010) Radiolabeling of substance P with lutetium-177 and biodistribution study in AR42J pancreatic tumor xenografted nude mice. Cell Mol Biol 56:12–17 Zhang H, Kanduluru AK, Desai P, Ahad A, Carlin S, Tandon N, Weber WA, Low PS (2018) Synthesis and evaluation of a novel 64Cu- and 67Ga-labeled neurokinin 1 receptor antagonist for in vivo targeting of NK1R-positive tumor xenografts. Bioconjug Chem 29:1319–1326 Bateman TM (2012) Advantages and disadvantages of PET and SPECT in a busy clinical practice. J Nucl Cardiol 19:3–11 Eagle H (1955) Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc Soc Exp Biol Med 89:362–364 Seabrook GR, Shepheard SL, Williamson DJ, Tyrer P, Rigby M, Cascieri MA, Harrison T, Hargreaves RJ, Hill RG (1996) L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol 317:129–135 Kanduluru AK, Low PS (2017) Development of a ligand-targeted therapeutic agent for neurokinin-1 receptor expressing cancers. Mol Pharm 14:3859–3865 Leamon CP, Parker MA, Vlahov IR, Xu LC, Reddy JA, Vetzel M, Douglas N (2002) Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical. Bioconjug Chem 13:1200–1210 Wayua C, Low PS (2015) Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor–expressing cancers. J Nucl Med 56:113–119 Li G, Low PS (2015) Synthesis and evaluation of a ligand targeting the somatostatin-2 receptor for drug delivery to neuroendocrine cancers. Bioorg Med Chem Lett 25:1792–1798 Hosseinimehr SJ, Tolmachev V, Orlova A (2012) Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today 17:1224–1232 Vegt E, Melis M, Eek A, de Visser M, Brom M, Oyen WJG, Gotthardt M, de Jong M, Boerman OC (2011) Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 38:623–632 Werle M, Bernkop-Schnürch A (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351–367 Böttger R, Hoffmann R, Knappe D (2017) Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLoS One 12:e0178943 Hillery AM, Lloyd AW, Swarbrick J (2002) Drug delivery and targeting: for pharmacists and pharmaceutical scientists. London: Taylor & Francis Srinivasarao M, Galliford CV, Low PS (2015) Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov 14:203–219 Srinivasarao M, Low PS (2017) Ligand-Targeted Drug Delivery. Chem Rev 117:12133–12164 Harrison T, Owens AP, Williams BJ, Swain CJ, Baker R, Hutson PH, Sadowski S, Cascieri MA (1995) Piperidine-ether based hNK1 antagonists 2: investigation of the effect of N-substitution. Bioorg Med Chem Lett 5:209–212 Kanduluru AK, Srinivasarao M, Low PS (2016) Design, synthesis and evaluation of a neurokinin 1 receptor-targeted near IR dye for fluorescence guided surgery of neuroendocrine cancers. Bioconjug Chem 27:2157–2165 Saria A (1999) The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 375:51–60 Muñoz M, Coveñas R (2014) Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids 46:1727–1750 Garcia-Recio S, Gascón P (2015) Biological and pharmacological aspects of the NK1-receptor. Biomed Res Int 2015:495704